Behavioural Intervention
Pharmacy Intervention for Medication Adherence
Recruiting0 awards3 criteria
Knoxville, Tennessee
This trial aims to help low-income individuals with multiple chronic conditions improve their medication adherence after being discharged from the hospital. The study will test a new pharmacy-led intervention that includes providing medications with zero copay
Popular Filters
Trials for PE Patients
Monoclonal Antibodies
Abelacimab vs Dalteparin for Blood Clot Prevention in Cancer Patients
Recruiting2 awardsPhase 3
Washington, District of Columbia
This trial compares a new medication, Abelacimab, to another treatment, Dalteparin, in patients with GI or GU cancer who have had blood clots. The goal is to see which treatment better prevents new clots and reduces bleeding risks.
Anticoagulant
Abelacimab vs Apixaban for Cancer-Related Blood Clots
Recruiting2 awardsPhase 3
Detroit, Michigan
This trial is testing abelacimab, a medication, to prevent blood clots in cancer patients who have had previous clots. It aims to see if it works better and causes fewer bleeding problems compared to a current treatment.
Thrombolytic Agent
Catheter-directed Thrombolysis for Pulmonary Embolism
Recruiting3 awardsPhase 4
Los Angeles, California
This trial compares two treatments for blood clots in the lungs in patients at higher risk of complications. One treatment uses only blood thinners, while the other combines blood thinners with a device that uses sound waves to break up clots. The goal is to see which treatment is better at reducing serious problems and death.
Thrombolytic Agent
Reduced-Dose Thrombolytic Therapy for Pulmonary Embolism
Recruiting1 awardPhase 3
Calgary, Alberta
This trial tests a smaller dose of a clot-busting drug combined with a blood thinner in patients with serious lung clots. The goal is to see if this approach is effective and safer than higher doses, reducing the risk of severe bleeding.
Trials for DVT Patients
Monoclonal Antibodies
Abelacimab vs Dalteparin for Blood Clot Prevention in Cancer Patients
Recruiting2 awardsPhase 3
Washington, District of Columbia
This trial compares a new medication, Abelacimab, to another treatment, Dalteparin, in patients with GI or GU cancer who have had blood clots. The goal is to see which treatment better prevents new clots and reduces bleeding risks.
Anticoagulant
Abelacimab vs Apixaban for Cancer-Related Blood Clots
Recruiting2 awardsPhase 3
Detroit, Michigan
This trial is testing abelacimab, a medication, to prevent blood clots in cancer patients who have had previous clots. It aims to see if it works better and causes fewer bleeding problems compared to a current treatment.
Anticoagulant
Low-Intensity Apixaban for Blood Clots
Recruiting2 awardsPhase 4
Boston, Massachusetts
This trial is testing low-intensity apixaban versus placebo for extended prevention of recurrence after provoked VTE in patients with at least one persistent provoking factor. The primary safety outcome is ISTH major bleeding at 12 months, and the primary efficacy outcome is symptomatic, recurrent VTE at 12 months.
Phase 3 Trials
Monoclonal Antibodies
Abelacimab vs Dalteparin for Blood Clot Prevention in Cancer Patients
Recruiting2 awardsPhase 3
Washington, District of Columbia
This trial compares a new medication, Abelacimab, to another treatment, Dalteparin, in patients with GI or GU cancer who have had blood clots. The goal is to see which treatment better prevents new clots and reduces bleeding risks.
Anticoagulant
Abelacimab vs Apixaban for Cancer-Related Blood Clots
Recruiting2 awardsPhase 3
Detroit, Michigan
This trial is testing abelacimab, a medication, to prevent blood clots in cancer patients who have had previous clots. It aims to see if it works better and causes fewer bleeding problems compared to a current treatment.
Thrombolytic Agent
Reduced-Dose Thrombolytic Therapy for Pulmonary Embolism
Recruiting1 awardPhase 3
Calgary, Alberta
This trial tests a smaller dose of a clot-busting drug combined with a blood thinner in patients with serious lung clots. The goal is to see if this approach is effective and safer than higher doses, reducing the risk of severe bleeding.
Trials With No Placebo
Monoclonal Antibodies
Abelacimab vs Dalteparin for Blood Clot Prevention in Cancer Patients
Recruiting2 awardsPhase 3
Washington, District of Columbia
This trial compares a new medication, Abelacimab, to another treatment, Dalteparin, in patients with GI or GU cancer who have had blood clots. The goal is to see which treatment better prevents new clots and reduces bleeding risks.
Anticoagulant
Abelacimab vs Apixaban for Cancer-Related Blood Clots
Recruiting2 awardsPhase 3
Detroit, Michigan
This trial is testing abelacimab, a medication, to prevent blood clots in cancer patients who have had previous clots. It aims to see if it works better and causes fewer bleeding problems compared to a current treatment.
Thrombolytic Agent
Catheter-directed Thrombolysis for Pulmonary Embolism
Recruiting3 awardsPhase 4
Los Angeles, California
This trial compares two treatments for blood clots in the lungs in patients at higher risk of complications. One treatment uses only blood thinners, while the other combines blood thinners with a device that uses sound waves to break up clots. The goal is to see which treatment is better at reducing serious problems and death.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.